Skip to main content
NVDA+0.85%AAPL+0.66%MSFT0.00%GOOGL+1.48%AMZN+1.79%TSM+3.03%SPCX+2.08%AVGO+4.11%META-1.24%TSLA+3.81%LLY+0.18%BRK-B-0.57%MU+3.24%SKHY+2.53%WMT-1.18%AMD+5.42%JPM+0.73%V-0.94%XOM-2.08%JNJ+0.70%ASMLa+2.80%MA-0.82%ABBV-0.06%INTC+3.60%1398.HK+2.15%CVX-1.61%0700.HK-0.31%COST-1.34%CSCO+1.43%KO-0.94%ORCL+4.48%UNH-0.31%PG-0.56%BAC+0.43%1816.HK+1.32%3988.HK+0.66%CAT+2.86%DELL+8.01%HD-0.16%PM+0.56%0857.HK-0.98%0939.HK+0.81%AMAT+2.25%AP2d+2.18%GE+3.18%1288.HK+0.60%LRCX+1.29%0005.HK-5.56%NVS+1.59%MS+2.06%USDJPY+0.64%NZDMXN+0.64%AUDJPY+0.60%EURUSD-0.56%USDMXN+0.55%AUDDKK+0.52%EURAUD-0.51%EURZAR-0.50%EURSEK-0.45%GBPUSD-0.43%GBPTRY+0.41%USDCHF+0.40%NZDJPY+0.39%GBPAUD-0.39%GBPZAR-0.39%CADJPY+0.37%AUDCHF+0.36%EURCNH-0.36%EURNZD-0.33%GBPHKD+0.32%EURHKD-0.32%EURSGD-0.31%USDDKK+0.31%USDCAD+0.29%GBPMXN-0.28%AUDNOK+0.27%EURCAD-0.26%CHFJPY+0.26%EURNOK-0.25%NZDUSD-0.24%SGDJPY+0.24%AUDCAD+0.23%USDPLN+0.22%CHFSEK-0.21%AUDSGD+0.21%GBPSGD-0.21%GBPJPY+0.20%AUDNZD+0.19%GBPNZD-0.18%USDZAR-0.18%NOKJPY+0.18%EURCHF-0.18%USDTRY+0.18%GBPCAD-0.17%USDILS+0.16%NZDCHF+0.16%USDSEK-0.14%EURGBP-0.12%CADCHF+0.11%EURPLN-0.09%EURJPY+0.09%NZDSGD+0.09%CHFSGD-0.07%USDNOK+0.06%EURCZK-0.05%GBPCHF-0.05%AUDUSD-0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%USDTHB-0.03%NZDCAD+0.03%PLNJPY+0.02%CHFNOK-0.01%EURDKK-0.01%USDSGD0.00%HG1+1.90%USOIL-1.54%GAUUSD+1.18%XAUUSD+1.18%COTTON-1.16%UKOIL-1.13%S1-1.07%XAGUSD+0.95%GAGUSD+0.95%C1-0.69%XPTUSD+0.40%W1-0.25%BTCUSD+0.87%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.18%ZECUSDT+6.33%DOGEUSD+20.65%XMRUSDT+0.91%LINKUSD+25.58%BCHUSDT+4.15%XLMUSD+0.35%UNIUSD-0.13%LTCUSD+17.89%SUIUSD+0.91%HBARUSDT-1.56%TONUSD+41.71%TAOUSDT+0.25%AAVEUSD-2.39%DOTUSDT-1.58%ICPUSDT-1.90%ONDOUSDT+0.10%WLDUSDT+0.14%ARBUSDT+0.04%JUPUSDT+0.66%INJUSDT+0.57%ATOMUSDT-1.55%STXUSDT-1.73%TIAUSDT-2.53%FETUSDT+2.84%PYTHUSDT-3.58%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT+0.48%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.16%POLUSDT-0.20%AXSUSDT+0.46%EOSUSDT+0.53%FARTCOINUSDT+1.90%DYDXUSDT+2.19%GALAUSDT+0.41%ORDIUSDT+1.75%RONINUSDT+1.89%NOTUSDT+1.92%NVDA+0.85%AAPL+0.66%MSFT0.00%GOOGL+1.48%AMZN+1.79%TSM+3.03%SPCX+2.08%AVGO+4.11%META-1.24%TSLA+3.81%LLY+0.18%BRK-B-0.57%MU+3.24%SKHY+2.53%WMT-1.18%AMD+5.42%JPM+0.73%V-0.94%XOM-2.08%JNJ+0.70%ASMLa+2.80%MA-0.82%ABBV-0.06%INTC+3.60%1398.HK+2.15%CVX-1.61%0700.HK-0.31%COST-1.34%CSCO+1.43%KO-0.94%ORCL+4.48%UNH-0.31%PG-0.56%BAC+0.43%1816.HK+1.32%3988.HK+0.66%CAT+2.86%DELL+8.01%HD-0.16%PM+0.56%0857.HK-0.98%0939.HK+0.81%AMAT+2.25%AP2d+2.18%GE+3.18%1288.HK+0.60%LRCX+1.29%0005.HK-5.56%NVS+1.59%MS+2.06%USDJPY+0.64%NZDMXN+0.64%AUDJPY+0.60%EURUSD-0.56%USDMXN+0.55%AUDDKK+0.52%EURAUD-0.51%EURZAR-0.50%EURSEK-0.45%GBPUSD-0.43%GBPTRY+0.41%USDCHF+0.40%NZDJPY+0.39%GBPAUD-0.39%GBPZAR-0.39%CADJPY+0.37%AUDCHF+0.36%EURCNH-0.36%EURNZD-0.33%GBPHKD+0.32%EURHKD-0.32%EURSGD-0.31%USDDKK+0.31%USDCAD+0.29%GBPMXN-0.28%AUDNOK+0.27%EURCAD-0.26%CHFJPY+0.26%EURNOK-0.25%NZDUSD-0.24%SGDJPY+0.24%AUDCAD+0.23%USDPLN+0.22%CHFSEK-0.21%AUDSGD+0.21%GBPSGD-0.21%GBPJPY+0.20%AUDNZD+0.19%GBPNZD-0.18%USDZAR-0.18%NOKJPY+0.18%EURCHF-0.18%USDTRY+0.18%GBPCAD-0.17%USDILS+0.16%NZDCHF+0.16%USDSEK-0.14%EURGBP-0.12%CADCHF+0.11%EURPLN-0.09%EURJPY+0.09%NZDSGD+0.09%CHFSGD-0.07%USDNOK+0.06%EURCZK-0.05%GBPCHF-0.05%AUDUSD-0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%USDTHB-0.03%NZDCAD+0.03%PLNJPY+0.02%CHFNOK-0.01%EURDKK-0.01%USDSGD0.00%HG1+1.90%USOIL-1.54%GAUUSD+1.18%XAUUSD+1.18%COTTON-1.16%UKOIL-1.13%S1-1.07%XAGUSD+0.95%GAGUSD+0.95%C1-0.69%XPTUSD+0.40%W1-0.25%BTCUSD+0.87%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.18%ZECUSDT+6.33%DOGEUSD+20.65%XMRUSDT+0.91%LINKUSD+25.58%BCHUSDT+4.15%XLMUSD+0.35%UNIUSD-0.13%LTCUSD+17.89%SUIUSD+0.91%HBARUSDT-1.56%TONUSD+41.71%TAOUSDT+0.25%AAVEUSD-2.39%DOTUSDT-1.58%ICPUSDT-1.90%ONDOUSDT+0.10%WLDUSDT+0.14%ARBUSDT+0.04%JUPUSDT+0.66%INJUSDT+0.57%ATOMUSDT-1.55%STXUSDT-1.73%TIAUSDT-2.53%FETUSDT+2.84%PYTHUSDT-3.58%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT+0.48%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.16%POLUSDT-0.20%AXSUSDT+0.46%EOSUSDT+0.53%FARTCOINUSDT+1.90%DYDXUSDT+2.19%GALAUSDT+0.41%ORDIUSDT+1.75%RONINUSDT+1.89%NOTUSDT+1.92%
EV

Evolus, Inc. (EOLS)

NASDAQ • Healthcare

$7.17
+$0.16 (+2.3%)
Market open

Last close at October 26, 2026 at 20:00 UTC

Open$7.06
Previous Close$7.17
Day Range$6.9 - $7.19
Avg. Volume (3M)758.1K
Market Cap$474.9M
52 Week Range
$3.86$9.31
Next EarningsIn 8 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$84M100%
Gross Profitminus cost of goods$57.1M68%

In plain terms: out of every $100 in revenue, Evolus, Inc. currently loses $10.

Fundamentals & Financials

Revenue (TTM)
$316.4M
Net Income (TTM)
-$34.3M
EPS (TTM)
-$0.52
ROA (TTM)
-13.84%
Current Ratio
1.7

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-26.3%Q1 2026$0.04
+28.6%Q2 2026-$0.1
+122.3%Q3 2026$0.01
Next

Nov 4

in 8 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +122.3%

Evolus topped revenue expectations as sales rose 21.2% to about $84.1 million in the second fiscal quarter of 2026, reported August 5, 2026, with revenue of $84.1 million versus an $81.5 million estimate (+3.1%, topped) and growth still centered on its Jeuveau medical aesthetics franchise. Gross profit reached roughly $57.2 million, keeping gross margin at 68.0%, while operating results remained negative with operating income of about -$4.5 million and an operating margin of -5.4%. Net income narrowed to around -$8.1 million, a 53.0% improvement from a year ago, as the company lapped a larger loss in the prior-year quarter. Cash generation was also negative, with operating cash flow of about -$3.6 million. For the next period, consensus calls for EPS of -$0.03 on revenue of $77.8 million.

Next report — what to expect

Evolus, Inc. (EOLS) reports on November 4, 2026. Wall Street’s next-period consensus calls for EPS of -$0.05 on revenue of $77.9 million. For trailing context, revenue grew +21.2% year over year last quarter. Historically, it has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About Evolus, Inc.

Evolus, Inc. develops and markets medical aesthetics treatments in the healthcare sector, centered on prescription products sold in the United States. The company, which trades on NASDAQ as EOLS, generated $297.2 million of revenue in FY2025 and operates within the specialty and generic drug manufacturing business.

Name
Evolus, Inc.
CEO
David Moatazedi
Website
www.evolus.com
Industry
Healthcare
Year Founded
2012
Employees
353

Today's Snapshot

AI-generated

EOLS is slightly higher at 7.19 so far today, in line with a flat sector. Earnings are due from EOLS on 4 November.

Trading Volume

Below 10d avg (640.3K)

239.6K

vs S&P 500 Today

Moderate Underperformance

-0.42%

Updated: October 27, 2026 at 16:39 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
EOLS is trading near 7.08 and exhibits downward pressure as price sits beneath most short- and medium-term moving averages while remaining above the long-term 200-day average, which moderates the decline. Momentum indicators lean negative with a weakening MACD and a CCI in sell territory, even as a very low stochastic suggests short-term oversold conditions. Trend strength is modest with an ADX around 20, and volatility is moderate with an ATR near 4.8% of price; on-balance volume shows accumulation despite price weakness. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$6.74 - $7.59
    Sell
  • RSI (14)40.56
    Neutral
  • Stochastic %K (14, 3, 3)19.09
    Buy
  • MACD Level (12, 26)-0.20
    Sell

Peers & Related Assets

AEONAEON Biopharma, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.